PRODUCT PIPELINE

Icagen is conducting clinical and preclinical studies in its core focus areas, which include the following:

  • Epilepsy and Pain             

             ICA-105665 is a novel opener of the KCNQ potassium ion channel which has

             demonstrated a broad spectrum of activity in preclinical models of both

             epilepsy and pain.  In Phase I safety studies, the compound was shown to be

             well tolerated in both healthy volunteers and in epilepsy patients.  ICA-105665

             was subsequently studied in patients with photosensitive epilepsy, with two of

             the four patients tested in the 400mg dose cohort showing a positive    

             response. This study was subsequently extended to doses of 500mg and

             600mg, but due to a serious adverse event in the 600mg dose cohort the

             study  was placed on clinical hold.  In an extension to the multiple ascending

             dose safety study in healthy volunteers, ICA-105665 continued to be well

             tolerated at doses up to 600mg.  The Company is currently discussing

             potential next steps with its advisors and with the FDA, with analysis of the

             complete data set from both studies ongoing.

  • Pain Control

              Icagen has a broad research effort directed at novel ion channel targets for

              pain control. In August, 2007, Icagen entered into a collaboration with

              Pfizer for the discovery and development of novel pharmaceuticals directed

             against three sodium channel targets.  In addition, Icagen is pursuing research

             directed at multiple ion channel targets in its pain control program.

  • Inflammatory Disorders

              Icagen has identified several ion channel targets that are expressed at high

              levels in some immune system cells and that may play an important role in

              modulating the inflammatory response.  Icagen has discovered compounds

              that are active in vitro against some of these targets, leading to decreases in

             calcium entry into immune  system cells, decreases in immune system cell

             proliferation, decreases in immune system cell migration into tissues and

             other measures of inflammatory responses.  Icagen has also demonstrated

             effects of our compounds in animal models of inflammatory diseases.  

                            

  • Senicapoc

              Senicapoc, formerly known as ICA-17043, has completed two proof of

              concept clinical trials for the treatment of asthma.  In all clinical

              studies senicapoc has demonstrated a favorable safety and tolerability profile. 

              While the Company does not plan to pursue further clinical development of

              senicapoc  for asthma, this program is a candidate for partnering or

              outlicensing

 

In addition to the areas noted above, Icagen is continuing to explore the human ion channel genome, for which it has completed the cloning of all human ion channel genes, to identify new therapeutic opportunities.

 

Next: Drug Candidates




 Contact Us     Directions      Site Map Copyright © Pfizer, Inc.   All rights reserved